Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Xing Tan, Hwan Seung Kim, Kimberly Baugh, Yanqin Huang, Neeraja Kadiyala, Marisol Wences, Nidhi Singh, Eric Wenzler & Zackery P Bulman. (2021) Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales. Infection and Drug Resistance 14, pages 125-142.
Read now
Read now
Wentao Ni, Guobao Li, Jin Zhao, Junchang Cui, Rui Wang, Zhancheng Gao & Youning Liu. (2018) Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. Infectious Diseases 50:7, pages 507-513.
Read now
Read now
Elizabeth A. Neuner & Jason C. Gallagher. (2017) Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence 8:4, pages 440-452.
Read now
Read now
Burke A. Cunha, Jeffrey Baron & Cheston B. Cunha. (2017) Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited. Expert Review of Anti-infective Therapy 15:3, pages 257-267.
Read now
Read now
Konstantinos Z. Vardakas, Dimitrios K. Matthaiou, Matthew E. Falagas, Elli Antypa, Asimoula Koteli & Eleni Antoniadou. (2015) Tigecycline for carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. Infectious Diseases 47:10, pages 751-753.
Read now
Read now
Articles from other publishers (28)
Theodoros Karampatakis, Katerina Tsergouli & Kinga Lowrie. (2023) Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis. Microbial Pathogenesis 179, pages 106090.
Crossref
Crossref
Cheng Len Sy, Pao-Yu Chen, Chun-Wen Cheng, Ling-Ju Huang, Ching-Hsun Wang, Tu-Hsuan Chang, Yi-Chin Chang, Chia-Jung Chang, Ing-Moi Hii, Yu-Lung Hsu, Ya-Li Hu, Pi-Lien Hung, Chen-Yen Kuo, Pei-Chin Lin, Po-Yen Liu, Ching-Lung Lo, Shih-Hao Lo, Pei-Ju Ting, Chien-Fang Tseng, Hsiao-Wei Wang, Ching-Hsiang Yang, Susan Shin-Jung Lee, Yao-Shen Chen, Yung-Ching Liu & Fu-Der Wang. (2022) Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. Journal of Microbiology, Immunology and Infection 55:3, pages 359-386.
Crossref
Crossref
Ying Shi, Jing Hu, Peiben Liu, Tingting Wang, Han Wang, Yun Liu, Quan Cao & Xiangrong Zuo. (2021) Ceftazidime–Avibactam-Based Versus Tigecycline-Based Regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients. Infectious Diseases and Therapy 10:4, pages 2721-2734.
Crossref
Crossref
Clement Yaw Effah, Emmanuel Kwateng Drokow, Clement Agboyibor, Shaohua Liu, Emmanuel Nuamah, Tongwen Sun, Lijun Miao, Jing Wang, Zhiwei Xu, Yongjun Wu & Xiaoju Zhang. (2021) Evaluation of the Therapeutic Outcomes of Antibiotic Regimen Against Carbapenemase-Producing Klebsiella pneumoniae: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Guangjun Fan, Liu Jin, Hansheng Bai, Kang Jiang, Jiao XieYalin Dong. (2020) Safety and Efficacy of Tigecycline in Intensive Care Unit Patients Based on Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 42:6, pages 835-840.
Crossref
Crossref
G. A. Klyasova. (2020) Current treatment options for infections caused by carbapenem-resistant Enterobacteriaceae in patients with hematological malignancies. Oncohematology 15:2, pages 92-107.
Crossref
Crossref
Lei Zha, Lingling Pan, Jun Guo, Neil French, Elmer V. Villanueva & Boris Tefsen. (2020) Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. Advances in Therapy 37:3, pages 1049-1064.
Crossref
Crossref
Fang Chen, Chuan Shen, Xiaoyun Pang, Zaili Zhang, Yuxiao Deng, Longzhi Han, Xiaosong Chen, Jianjun Zhang, Qiang Xia & Yongbing Qian. (2019) Effectiveness of tigecycline in the treatment of infections caused by carbapenem‐resistant gram‐negative bacteria in pediatric liver transplant recipients: A retrospective study. Transplant Infectious Disease 22:1.
Crossref
Crossref
Akosua A. Agyeman, Phillip J. Bergen, Gauri G. Rao, Roger L. Nation & Cornelia B. Landersdorfer. (2020) Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections (a meta-analysis dataset). Data in Brief 28, pages 104907.
Crossref
Crossref
Lei Wang, Xiang Tong, Jizhen Huang, Li Zhang, Dongguang Wang, Man Wu, Tao Liu & Hong Fan. (2020) Triple Versus Double Therapy for the Treatment of Severe Infections Caused by Carbapenem-Resistant Enterobacteriaceae: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 10.
Crossref
Crossref
E. Durante-Mangoni, R. Andini & R. Zampino. (2019) Management of carbapenem-resistant Enterobacteriaceae infections. Clinical Microbiology and Infection 25:8, pages 943-950.
Crossref
Crossref
Chau-Chyun Sheu, Ya-Ting Chang, Shang-Yi Lin, Yen-Hsu Chen & Po-Ren Hsueh. (2019) Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. Frontiers in Microbiology 10.
Crossref
Crossref
Jinhong Gong, Dan Su, Jingjing Shang, Hai Yu, Guantao Du, Ying Lin, Zhiqiang Sun & Guangjun Liu. (2019) Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases. Medicine 98:38, pages e17091.
Crossref
Crossref
Sarah C. J. Jorgensen & Michael J. Rybak. (2018) Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms. Infectious Diseases and Therapy 7:4, pages 401-405.
Crossref
Crossref
Zihan Chen & Xiaoyan Shi. (2018) Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine 97:38, pages e12467.
Crossref
Crossref
Natalie Gofman, Kim To, Marc Whitman & Edgar Garcia-Morales. (2018)
Successful treatment of ventriculitis caused by
Pseudomonas aeruginosa
and carbapenem-resistant
Klebsiella pneumoniae
with i.v. ceftazidime–avibactam and intrathecal amikacin
. American Journal of Health-System Pharmacy 75:13, pages 953-957.
Crossref
Crossref
Jesús Rodríguez-Baño, Belén Gutiérrez-Gutiérrez, Isabel Machuca & Alvaro Pascual. (2018) Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clinical Microbiology Reviews 31:2.
Crossref
Crossref
Sarah Christina Jane Jorgensen & Michael Joseph Rybak. (2018) Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:4, pages 444-461.
Crossref
Crossref
Ting-Ting Geng, Xin Xu & Man Huang. (2018) High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Medicine 97:8, pages e9961.
Crossref
Crossref
David M. Jacobs, M. Courtney Safir, Dennis Huang, Faisal Minhaj, Adam Parker & Gauri G. Rao. (2017) Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review. Annals of Clinical Microbiology and Antimicrobials 16:1.
Crossref
Crossref
Chaitra ShankarLaura E. B. NabarroShalini AnandanBalaji Veeraraghavan. (2017) Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram–Negative Organisms?. Microbial Drug Resistance 23:4, pages 437-446.
Crossref
Crossref
Wentao Ni, Yuliang Han, Jie Liu, Chuanqi Wei, Jin Zhao, Junchang Cui, Rui Wang & Youning Liu. (2016) Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections. Medicine 95:11, pages e3126.
Crossref
Crossref
Xiaomai Wu, Yefei Zhu, Qiuying Chen, Liuyang Gong, Jian Lin, Dongqing Lv & Jiaxi Feng. (2016) Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study. BioMed Research International 2016, pages 1-7.
Crossref
Crossref
Jesús Rodríguez-Baño, José Miguel Cisneros, Nazaret Cobos-Trigueros, Gema Fresco, Carolina Navarro-San Francisco, Carlota Gudiol, Juan Pablo Horcajada, Lorena López-Cerero, José Antonio Martínez, José Molina, Milagro Montero, José R. Paño-Pardo, Alvaro Pascual, Carmen Peña, Vicente Pintado, Pilar Retamar, María Tomás, Marcio Borges-Sa, José Garnacho-Montero & Germán Bou. (2015) Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enfermedades Infecciosas y Microbiología Clínica 33:5, pages 337.e1-337.e21.
Crossref
Crossref
Francesco G De Rosa, Silvia Corcione, Rossana Cavallo, Giovanni Di Perri & Matteo Bassetti. (2015)
Critical issues for
Klebsiella pneumoniae
KPC-carbapenemase producing
K. pneumoniae
infections: a critical agenda
. Future Microbiology 10:2, pages 283-294.
Crossref
Crossref
Petros I. Rafailidis & Matthew E. Falagas. (2014) Options for treating carbapenem-resistant Enterobacteriaceae. Current Opinion in Infectious Diseases 27:6, pages 479-483.
Crossref
Crossref
L.S. Tzouvelekis, A. Markogiannakis, E. Piperaki, M. Souli & G.L. Daikos. (2014) Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clinical Microbiology and Infection 20:9, pages 862-872.
Crossref
Crossref
José Garnacho-Montero & Carmen Ferrándiz-Millón. (2014) High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can. Critical Care 18:3, pages 157.
Crossref
Crossref